Bonds … Kabuki Theater

Early Session

What Is The Bond Market Saying About Itself?

With all the media press and hype, you would think bond yields have just spiked above 15%.

We have to remind ourselves that everything, that is, every move, every press release, every interview, is controlled.

Controlled for the purpose of “deception” as Livermore put it during an interview with Wyckoff in 1921.

With that in mind, who stands to benefit from the sharp move lower in bonds?

Seems like the obvious answer is, the short-term shorts and the longer-term bulls; especially if the hapless ‘hedge funds’ have jumped on the band wagon to short the market.

Bond (TLT) Analysis:

What Is The Market Saying About Itself?

The sharp move lower over the past four trading sessions, has likely cleared out the weak hands and emboldened the shorts to short some more.

The problem is (for the bears), we’re at a 50% retrace of the March 18th low. In addition, price action has just penetrated well known support.

That puts the bond market (TLT) in spring position.

We can see from today’s open, TLT is gap-higher and now, just below the support level.

We’re at the danger point, where the risk of going long is least (not advice, not a recommendation).

Because the four-day down-draft was so swift, don’t expect TLT to launch into an instant and sustained rally.

There may be quite a bit of testing (if and) before this market heads higher.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Rule of Alternation: Biotech

Early Session

What Happened Last Time … Won’t Happen This Time

We have four more trading days until the end of the Third Quarter. It’s unlikely that biotech (SPBIO) is going to make a new quarterly high.

This morning’s early action has LABD (3X inverse SPBIO) essentially unchanged to slightly lower; higher for SPBIO.

The weekly chart of SPBIO, above, has been inverted to mimic the inverse fund LABD … but without the tracking (bias) errors.

The “tight” area of action has been expanded in the next chart:

We can see the wide, high volume bar from the week of 8/27, is being tested by the subsequent weeks and their upward action.

This is normal market behavior that has probably been repeating itself since the buttonwood tree.

Alternating Action:

The difference this time around, we’ve already had the ‘low to upward thrust’ (for LABD) that was negated last week with a test.

That test has now reversed as seen on the 4-Hour chart (inverted SPBIO) below:

Both downward thrusts (September 17th, and 23rd) finished the day at or near their session lows.

The ‘rule of alternation’, from Prechter’s Elliott Wave discussions, essentially says that; what happened last time, will not happen this time.

That leaves two scenarios for SPBIO and LABD.

Scenario, No. 1

SPBIO reverses from here and goes on to make new daily, weekly highs.

Scenario, No. 2

SPBIO continues its downward reversal into the next leg lower; potentially to the Fibonacci projection target (not shown) of 161.8%.

That would put SPBIO, at or near the 3,873 level … a decline of nearly 62%, from last Friday’s close.

Force Index:

Since the inverse fund LABD is heavily traded (2mil – 3mil, shares per day), we can use it as a good indicator of professional trader commitment

I say ‘professional’ because, as incredible as it may seem, the majority of market participants (the amateurs) do not understand or can’t grasp the concept, the big money is made on the downside.

The trading books that regale stories of massive gains, were typically trades to the downside … probably the most famous of which, was Livermore’s well documented short position during The Panic of 1907.

I’ve even talked to a former broker (for a firm that has 15,000 locations nationwide) who asked me when I was discussing the markets (and I quote): “What’s an inverse fund?”

I kid you not.

As touched on yesterday with Random Notes, the level of complacency, stupidity and ignorance has reached levels that are not going to be repeated in our lifetimes.

Market participants are either going to be wiped-out … or they’re going to get very smart, very fast.

I’m personally going with the ‘wiped-out’ scenario as it’s extremely difficult to come up to speed on a complicated topic (reading price action) while your account is being decimated.

Which brings us to the Force-Index chart of LABD:

This chart’s a little different than the rest.

The Force Index section (the lower panel) has been expanded to show the nuances of thrust action.

Even all the way back to the major thrust lower on August 23rd, we can see, downward thrust energy has been dissipating.

Recently, as shown with the blue arrow, downward thrust has evaporated altogether.

Summary:

It appears from the 4-Hour chart of LABD, we’re potentially at a major point of inflection (not advice, not a recommendation).

The rest of the indices (except the miners) are at or near their all time highs … with valuations (P/E ratios) stretched to the highest on record; going all the way back to 1962, if memory serves.

SPBIO is the only major index that’s about to post three down quarters in a row.

Obviously we’re short this sector via LABD (not advice, not a recommendation) with the understanding that anything can happen.

This market (SPBIO) along with the others could reverse and move to new highs.

However, at this juncture, it looks like the air’s coming out of biotech … slowly, at first.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Goes Down … Stays Down

Livermore’s Rules; Going Short

From his 1923 book (Reminiscences), Livermore’s rules for going short were fairly blunt:

‘I’m not interested in shorting a stock until it goes down and stays down’

It’s possible that’s what we’ve got with real estate, IYR.

This past trading week was IYR’s opportunity to regain balance and attempt to move higher.

It didn’t happen.

Instead, we got a struggle for several days; ultimately breaking lower, late during the Friday session.

Note the volume increased markedly from the day prior.

Summary:

We’re short this sector (not advice, not a recommendation) via DRV. There are times were significant reversals start slow and take time to build … this could be one of those.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

‘When’s the next Bear Market?’

9:47 a.m., EST

ZeroHedge Report Acts Like It’s Not Here

Jerimiah Babe says “Have You Looked Outside?”

If the mainstream media is good for anything, it’s the ability to keep the herd, the retail, (Robinhood kids, et al.) fully distracted until it’s absolutely too late for action.

Even though this report from ZeroHedge gives all kinds of ‘signals’ saying we’re not there yet; It even goes as far as showing there’s no yield curve inversion. Of course that means ‘no risk’ of bear market.

Then going on to say, ‘None of these measures indicate a bear market is near’. I mean, you can’t make this stuff up.

What’s the table above (yesterday’s close) say about what’s really going on?

At this point it’s obvious the media are not going to discuss the on-going bear market in biotech, SPBIO.

Doing so, would require some kind of investigation as to why? That would open Pandora’s box and have everyone digging for truth … something to be avoided (censured) at all costs.

Amateurs always want (need) to know why.

Livermore was never concerned with the why. He looked for ‘what’. What is the price action doing now or what is it likely to do.

As Wyckoff said, ‘the why always comes out later … after the fact’

‘Why’ is a useless trading strategy.

However, in the case of biotech, we can take a good guess what the ‘why’ is all about.

Fall and Winter are very close now. As this interview with Stew Peters reveals, Fall and Winter are when we get the real picture of ‘side effects’.

Biotech is ahead of the pack on the downside and for good reason.

Positioning:

Positions have not changed except for additions of LABD as SPBIO declines and LABD heads higher (not advice, not a recommendation).

As a reminder, this site’s not interested in day trading or even swing trading unless that’s all the market offers.

No, we’re interested in positioning strategically.

This type of trading is modeled after the host’s twenty-four years of experience with aircraft flight test and certification.

A typical project would take five to seven years to complete; have a near infinite number of complex stages along the way with each one a profession unto itself.

At this juncture, biotech may be poised for the largest implosion ever seen in market history.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

After the ‘plug is pulled …’

Jerimiah Babe:

‘The real money’s going to be made, after the plug is pulled’

Well, that’s close.

Actually, the real money’s made on the way down … when the plug is pulled … not after.

‘After’, is when you take the huge gains from the short side and then allocate that to areas which stand to recover … or at least have a good chance of recovery.

It’s a two-step process:

Nobody demonstrated that better than Livermore himself during the panic of 1907.

It’s probably no surprise that panic was potentially a fabricated event (sound familiar?).

It laid the groundwork for the Federal Reserve act of 1913.

Operating in parallel, we have the following:

Titanic engineering design approval: July of 1908.

Construction begins: March 1909.

Sea trials: Early April, 1912

Titanic ‘sinks’: April 15, 1912.

April 15th, is tax day … coincidence … no.

Whether or not there really is a ship (or which one is) at the bottom of the Atlantic, is immaterial.

What’s important, was that it all may have been a controlled demolition of the financial system so that it cold be ‘reset’ to allow fractional reserve banking.

The fly in the ointment? Unexpectedly, Livermore owned the market at the bottom. He could have single handedly destroyed the financial system by executing more short selling.

That’s when J.P. Morgan (possibly chief cook and bottle washer for the ‘reset’) called him in to appeal to Livermore’s ‘patriotism’; to not destroy the market. You can’t make this stuff up.

So, it’s time to reset the system every hundred years or so.

Just like it’s time to have a medical ‘incident’ and reduce the population every hundred years or so:

2019: ‘The Speck’

1918: ‘Espana’ Flu

1817: ‘Cholera’

1718: ‘Plague’

How does this relate to the markets? For this update, the preamble above, brings us to gold (GLD):

Gold (GLD) Analysis:

It’s no secret, price action in GLD and the miners (GDX, GDXJ), has been analyzed for months as bearish.

The weekly chart shows GLD, right at the edge of a terminating wedge; about to break lower:

The measured move … to around GLD ~ 120, is exactly at the Fibonacci 161.8%, projection (not shown).

If there’s a wedge breakdown, we have two separate measurement techniques targeting the same area.

The next chess move, is probably not going to be dollar destruction.

No. The next move is likely to be as stated before, supply chain shut-down with the objective of ‘starve them out’.

In a prior update, when that statement was made, it may have sounded extreme. Now, we have this interview and time stamp (8:11), where we get the exact same thing.

Take Action:

This article, just out on ZeroHege is a good one-stop shop to start or continue being out in front of ‘events’.

Here’s a brief video of one man’s action, in action:

Four hens, a rooster, in an urban setting (houses on three sides).

The rooster was not part of the plan. If you look closely, you can see his ‘No Crow‘ collar … it works most of the time.

He was unexpected but is now seen as an asset.

He keeps the hens under control (otherwise, they fight) and gets them all back in the coop at night.

Is it a hassle: Yes.

Is it messy: Yes.

Will the neighbors not care about the crowing, be clamoring (and paying with cash, gold, silver) for eggs and chicks three months from now, if/when food shipments are cut off? Probably, yes

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

‘Sitting Tight’

12:32 p.m., EST

Livermore: ‘Get right and sit tight’

Inverse biotech fund LABD, in trading channel

A steady sustained decline of tracking index SPBIO, is the best environment for highly leveraged (3X-inverse) fund LABD.

Biotech continues to be one of, if not the downside leader.

There has been no major break lower (LABD higher) that would draw attention to the index. That’s good in a way; it allows one to open positions (not advice, not a recommendation) while price action is relatively quiet.

It’s still a while before the close. LABD could even finish slightly lower and remain in the trading channel shown above.

Self-Employment Is Key:

It’s stories like this that highlight one way (if not the only way) to avoid being sucked into the first round of injections is to generate your own income.

It seems that everyone jumps on the bandwagon and tells us ‘how bad it is’ … very few do the work and show what can be done about the current reality.

From a financial market perspective, shorting biotech looks like the highest probability set-up (not advice not a recommendation) until such time that price action says ‘get out’.

So, that’s this site’s approach to generating income and being separate from any large (mandate enforcing) corporation.

‘Knock and Talk’

One last note on taking action. This is an example; offering a perspective on what can be done if there is a knock at the door.

Narrow your focus of ‘influencers’ to those who actually provide a service. Reduce or eliminate exposure to those who continue to peddle the fear without any kind of plan.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Livermore, Wyckoff, & Loeb

Buffett’s not on the list

After thirty-four years of researching the markets, focus has narrowed to three masters from the early 1900s; providing a solid framework for addressing the markets of today.

More detail on these masters can be found at this link.

Summarizing their knowledge as follows:

Strategy, Tactics, & Focus

This update demonstrates how those tenets are being implemented.

Strategy:

In Livermore’s fictional autobiography (Reminiscences), he muddled around for years before identifying his niche.

That is:

‘What’s going to (or what’s likely to) happen in a big way.’

That insight has been used to identify the biotech sector as ripe for complete (and well deserved) implosion; more so than any other sector in the market.

For many months, the case continues to build for collapse.

Here’s just one more brick in the wall; providing even more support for implosion.

Tactics:

Wyckoff committed his entire professional life to decoding the market and its moves.

He is (as far as available data shows) the father of technical analysis.

Terms like ‘support’, ‘resistance’, ‘accumulation’, ‘distribution’, did not exist before is treatise, “Studies In Tape Reading”, published in 1910.

His bottom line:

Price is moved by a force of its own; having nothing to do (in a causal way) with fundamentals:

‘What is the market saying about itself.’

The biotech sector SPBIO, is tag-teaming with gold miners GDX (and GDXJ), for downside leadership.

SPBIO finished the week down -27.5%, from its February 9th (2021) high; running a close second to GDX, which finished the week down – 27.6%, from its August 5th (2020) high.

From a speed-of-decline standpoint, biotech’s in the lead.

Focus:

Loeb’s brutal admonition was: ‘The naïve, lazy, mediocre, ignorant and the incompetent “diversify”.

His follow-on corollary was: ‘Real market opportunities are few. If one is discovered, it must be used to its maximum extent.’

Loeb’s assessment of those in the market, is not much different from Wyckoff’s:

“The average man never makes a success of Tape Reading.

Right you are! The average man seldom makes a success of anything.” (emphasis is Wyckoff’s).

From the above list, ignorance can be fixed through determination, study, tenacity and the never-ending search for (market) truth.

The others, not so much.

Using Loeb’s tenet, that is, ‘focus’, we’ve taken it and have gone short and continue to go short (not advice, not a recommendation), the biotech sector via LABD.

Summary:

There’s no guarantee the short trade will work out; yielding a significant gain.

Any number of things can happen:

Internet outage, power outage, terrorist attack, supply chain and transportation shut-downs … literally, anything.

However, being short (from a personal standpoint) is better than wringing one’s hands, cowering in fear, looking to the (bought and paid for) financial media to provide direction on what to do in this unstable environment.

Epilogue:

By using the life’s work of Livermore, Wyckoff & Loeb, its been determined, being short biotech (and possibly the mining sector) is the appropriate market stance.

With the caveat that even now, one might need to exit the trade; it still appears at this juncture, the on-going short (not advice, not a recommendation) is the most focused profit opportunity given the current environment.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Building The Case For Collapse

2:46 p.m., EST

Biotech SPBIO, Down

Inverse LABD, Up

Inverse biotech, LABD above, is confirming a pivot.

The magenta arrows show contact points morphing into a pivot that has two more contacts.

The new trendline was copied, then pasted to the far left of the chart.

It’s clear the new (pivot) trend is identical to the one created when LABD bottomed out this past February.

While the overall markets (S&P, Dow, COMPX) are still showing green, biotech looks like it has started the next leg down.

The original short position via LABD, has remained intact (not advice, not a recommendation) and has been increased five times (including today) since the beginning of this month.

In our view, biotech’s signaling the potential for a very dangerous situation.

Biotech’s headed down and we’re already short; not advice, not a recommendation..

As Livermore said a hundred years ago, ‘surprises tend to happen in the direction of trend.’

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Deep Dive: Biotech

Biotech Reversal

Downside Projections

Nuremberg 2.0

For what seems the longest time, a recurring focus of this site has been the biotech sector.

Specifically, the IBB (ETF) and SPBIO (Index).

There’s good reason for that. In this update, we’ll go deeper into the downside opportunity.

Biotech Reversal:

SPBIO, topped out on February 9th this year. The IBB (ETF) topped one day later.

Both went on to form a Quarterly reversal bar; indicating a long term change in character.

Of the two, SPBIO has showed more weakness having posted monthly lower lows for three successive months.

That relative weakness over the IBB index, has resulted in focusing on the inverse of SPBIO; specifically the 3X inverse, LABD.

Working with leveraged inverse funds is only profitable on a short-term basis or when the underlying index is in a persistent down-trend.

Otherwise, typical market chop results in value erosion of the inverse fund (not advice, not a recommendation).

For the reasons discussed in the last section below (Nuremburg 2.0), we’re anticipating the index to have a sustained and persistent drop to much lower levels.

Downside Projections:

Going way back to Reminiscences of a Stock Operator and the Wyckoff Stock Market Institute training materials, both in their own way indicated a speculative position was only entered if there was sufficient potential.

Livermore’s 10-points or more and Wyckoff’s cause and effect

In Wyckoff’s case, the ’cause’ was price action congestion built up in the P&F chart.

The ‘effect’ was the resulting move.

Which brings us to now:

Many times on this site, we’ve said biotech has built up congestion in a way, when it reverses and begins its decline, price action itself will create lower targets.

We’ll present two charts showing how that’s happening.

The first P&F chart in this update and provided below, has a projected downside target for IBB around, 116 – 120 area:

Note, the downside is not to scale as the real location is far below the noted area.

Biotech IBB, then went on to post lower action. That in turn has resulted in an updated downside target:

Once again, the downside is not to scale.

It’s apparent, as IBB heads lower, it successively builds lower targets and it’s only (potentially) just getting started.

The weekly chart of IBB below, spells it out:

If and when IBB price action gets to the initial targets, it enters a congestion area that will (by that time) be over seven years wide.

If the trend is still down, that congestion in turn would target even lower levels.

The “-80%” interestingly enough, comes from a quote by Steven Van Metre at this link.

That 80% drop also corresponds to a downside Fibonacci (not shown) projection of 423.6%, on the above chart.

Nuremberg 2.0

This phrase has become so ubiquitous you can do a search for it.

So far, not a single mainstream financial site or YouTuber (still on that platform) has mentioned this fact in their analysis.

The speck injections are mass genocide and intended as such.

Two recent events resulting from injections are here and here.

If all of a sudden, injected pilots can’t fly (the first link), how are goods going to be transported?

Not generally known to the public, commercial air-transport is also used to haul freight (while carrying passengers).

Exactly how all of this (world crime) will break is unknown.

If and when it does, the result in the biotech sector as well as equities in general, could be successive air-pockets all the way down.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Breaking Down Biotech

Was last week the correction?

Is it over?

To provide perspective on that question, we need to go back in time.

First, to Dr. Elder’s “Entries & Exits“, published in 2006.

Then, way back to “Reminiscences“, published in 1923.

As a reminder, we’re looking at biotech (SPBIO) from the perspective of being short the market.

The primary vehicle for that short, is highly leveraged inverse fund, LABD.

The last update gave a hint at the desired timeframe.

If the markets are in the process of reversing, ultimately going to the long awaited (since 2009), final draw-down (i.e. crash), then a likely bottom would occur where they (almost) always occur; during the third week of October.

In a nutshell, that’s the time frame.

Conversely, price action is the final arbiter. If biotech winds up effectively saying ‘not now’, well then, it has the final say.

Back to ‘Entries & Exits’.

One of the traders highlighted in the book (in addition to Weis), was William Doane; former Head Technician for Fidelity.

His timeframe is much longer than the typical market participant. He, like Weis are looking at monthly, quarterly and yearly charts.

That fact in and of itself, provides an edge.

One of the main take-aways from his section was (paraphrasing):

‘The first correction is the hardest. If you can get through that, it’s typically smooth sailing from then on’.

The biotech short via LABD (not advice, not a recommendation) may be at that point now. Painful to watch but necessary.

Next, we go to ‘Reminiscences’.

Those who have read the book, know all about ‘Turkey’; Mr. Partridge.

As the book states, he was much older than the rest who frequented the brokerage. Also, he did not appear to be that active in the markets (thus minimizing his transactions). He was interested in the big move.

The admonition from Partridge, was: ‘Don’t lose your position’. Don’t exit out, expecting a pull-back … that ultimately never comes.

So, we have two examples; three if you include Weis that begin from the very long time-frames and work inward.

Now, on to the market:

The long term, Quarterly analysis has already been done; linked here.

The chart in the link, is from last quarter and since then, (during this quarter), we’ve made new lows.

On the fundamental side, evidence is building by the day on what the ‘speck’ protection is all about.

If you’re really interested in the big picture, here’s a link to a five-plus hour presentation that spells it all out.

Here’s J. P. Sears’ take on the same thing.

SPBIO, the daily chart:

The SPBIO, has been inverted and annotated

We’re currently between support and resistance.

Momentum indicators MACD, on the Monthly and Weekly remain in a downtrend.

Using IBB, as the proxy for Quarterly momentum (not enough data for SPBIO), the indicator is flat.

Momentum’s in favor of (maintaining) a short position; not advice, not a recommendation.

The monthly chart of SPBIO (inverted), has price action coming back to former resistance (now support). This is normal market behavior.

Recall, that on the downside, if there is some kind of ‘event’, markets can slice through apparent support levels with ease.

With that in mind, on the inverted chart above, the next major ‘resistance’ level may or may not be of consequence.

Summary:

Each trading week is important.

However, next week will likely a pivotal one; providing more information on whether to maintain short or exit and stand aside; not advice, not a recommendation.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.